Table 2.
Immunoreactivity of KGH-R1 mAb in human tumours and corresponding normal tissues
| Tumour | Cases | Immunoreactivity (HSCOREsa) | |
|---|---|---|---|
| Primary tumour tissues | Normal tissues | ||
| Colorectal cancer | 30 | 208.69 ± 84.40 | 6.88 ± 1.53 |
| Gastric cancer | 30 | 155.29 ± 87.50 | 7.86 ± 2.79 |
| Oesophageal cancer | 30 | 163.73 ± 66.00 | 8.50 ± 3.28 |
| Bladder cancer | 30 | 146.76 ± 95.36 | 8.10 ± 2.43 |
| Lung adenocarcinoma | 30 | 238.63 ± 72.00 | 7.00 ± 1.77 |
| Lung squamous cell carcinoma | 30 | 178.26 ± 83.99 | 7.00 ± 1.77 |
| Lung small cell carcinoma | 30 | 134.38 ± 91.58 | 7.00 ± 1.77 |
| Papillary thyroid carcinoma | 30 | 239.33 ± 75.51 | 8.43 ± 2.32 |
| Hepatocarcinoma | 30 | 184.38 ± 96.75 | 11.29 ± 5.51 |
| Prostate carcinoma | 30 | 114.77 ± 70.59 | 13.00 ± 4.24 |
| Breast cancer | 30 | 197.46 ± 56.33 | 9.23 ± 3.19 |
| Endometrial cancer | 30 | 139.29 ± 86.00 | 15.75 ± 5.72 |
| Glioma | 30 | 97.60 ± 8.85 | 17.30 ± 8.32 |
| Renal cell carcinoma | 30 | 117.50 ± 73.86 | 16.00 ± 5.85 |
aMean ± SD